UNION therapeutics A/S financials
UNION therapeutics A/S
5299000CU2DGFP8LJ124 | Line item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Income statement | |||
| Revenue | DKK 621.0K | DKK 2.3M | DKK 34.4M |
| Administrative expenses | DKK 27.5M | DKK 22.1M | DKK 31.6M |
| Operating profit (EBIT) | -DKK 87.7M | -DKK 160.0M | -DKK 183.6M |
| Finance costs | DKK 19.0M | DKK 17.4M | DKK 38.8M |
| Profit before tax | -DKK 104.2M | -DKK 174.8M | -DKK 219.8M |
| Income tax expense | -DKK 5.3M | -DKK 5.4M | -DKK 5.5M |
| Profit for the year | -DKK 98.9M | -DKK 169.4M | -DKK 214.3M |
| Total comprehensive income | -DKK 98.9M | -DKK 169.4M | -DKK 214.3M |
| Per share | |||
| Basic EPS | DKK -13.00 | DKK -23.00 | DKK -32.00 |
| Diluted EPS | DKK -13.00 | DKK -23.00 | DKK -32.00 |
| Free cash flow / share | DKK -11.43 | DKK -21.73 | DKK -23.63 |
| Cash flow statement | |||
| Net cash from operating activities | -DKK 87.0M | -DKK 160.0M | -DKK 158.1M |
| Net cash from investing activities | DKK 0 | -DKK 113.0K | -DKK 178.0K |
| Purchase of PP&E (capex) | DKK 0 | DKK 113.0K | DKK 178.0K |
| Net cash from financing activities | DKK 28.3M | DKK 96.7M | DKK 61.4M |
| Repayments of borrowings | DKK 0 | DKK 5.1M | DKK 126.0K |
| Lease liability payments | DKK 851.0K | DKK 796.0K | DKK 564.0K |
| Net change in cash | -DKK 58.7M | -DKK 63.4M | -DKK 96.8M |
| Balance sheet | |||
| Total assets | DKK 61.2M | DKK 120.2M | DKK 185.7M |
| Non-current assets | DKK 17.0M | DKK 18.2M | DKK 17.9M |
| Property, plant & equipment | DKK 474.0K | DKK 1.3M | DKK 1.0M |
| Current assets | DKK 44.2M | DKK 101.9M | DKK 167.8M |
| Cash & equivalents | DKK 37.6M | DKK 95.3M | DKK 159.0M |
| Total equity | -DKK 150.1M | -DKK 61.6M | -DKK 27.7M |
| Non-current liabilities | DKK 33.5M | DKK 10.5M | DKK 136.8M |
| Long-term borrowings | DKK 0 | DKK 0 | DKK 107.2M |
| Lease liabilities (non-current) | DKK 0 | DKK 543.0K | DKK 221.0K |
| Current liabilities | DKK 177.8M | DKK 171.2M | DKK 76.6M |
| Current portion of long-term borrowings | DKK 122.1M | DKK 114.4M | DKK 0 |
| Lease liabilities (current) | DKK 543.0K | DKK 817.0K | DKK 814.0K |
| Derived metrics | |||
| Free cash flow | -DKK 87.0M | -DKK 160.1M | -DKK 158.3M |
| Operating margin | -14126.6% | -6961.4% | -533.9% |
| Net margin | -15929.5% | -7369.6% | -623.1% |
| Return on equity | 65.9% | 275.0% | 774.0% |
| Cash conversion ratio | 0.88× | 0.94× | 0.74× |
| Capex coverage | — | -1415.75× | -888.06× |
| Other reported items | |||
| Adjustments To Reconcile Profit Loss Other Than Changes In Working Capital | DKK 11.7M | DKK 19.6M | DKK 52.7M |
| Cash | — | DKK 95.3M | DKK 159.0M |
| Current Deferred Income Including Current Contract Liabilities | DKK 0 | DKK 621.0K | DKK 2.9M |
| Current Tax Assets Current | DKK 5.5M | DKK 5.5M | DKK 5.5M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | DKK 1.0M | -DKK 332.0K | DKK 2.4M |
| Equity and Liabilities | DKK 61.2M | DKK 120.2M | DKK 185.7M |
| Finance Income | DKK 2.5M | DKK 2.7M | DKK 2.7M |
| Income Taxes Refund Classified As Operating Activities | DKK 5.3M | DKK 5.4M | DKK 5.5M |
| Increase Decrease In Working Capital | DKK 6.7M | DKK 18.0M | DKK 1.2M |
| Increase Decrease Through Conversion of Convertible Instruments | — | DKK 23.5M | DKK 57.5M |
| Increase Decrease Through Exercise of Warrants Equity | DKK 600.0K | DKK 45.0K | DKK 201.0K |
| Increase Decrease Through Sharebased Payment Transactions | DKK 9.9M | DKK 9.3M | DKK 17.6M |
| Intangible Assets Other Than Goodwill | DKK 16.6M | DKK 16.6M | DKK 16.6M |
| Interest Paid Classified As Operating Activities | DKK 1.0K | DKK 106.0K | DKK 1.1M |
| Interest Received Classified As Operating Activities | DKK 1.6M | DKK 2.7M | DKK 401.0K |
| Issue of Equity | — | DKK 102.6M | DKK 62.0M |
| Issued Capital | DKK 763.0K | DKK 761.0K | DKK 710.0K |
| Liabilities | DKK 211.3M | DKK 181.8M | DKK 213.4M |
| Noncurrent Portion of Noncurrent Notes and Debentures Issued | DKK 33.5M | DKK 0 | DKK 19.4M |
| Other Comprehensive Income | DKK 5.0K | -DKK 9.0K | DKK 6.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | DKK 5.0K | -DKK 9.0K | DKK 6.0K |
| Other Current Payables | DKK 8.9M | DKK 11.3M | DKK 20.2M |
| Other Current Receivables | DKK 1.1M | DKK 1.1M | DKK 3.3M |
| Other Noncurrent Receivables | DKK 0 | DKK 388.0K | DKK 294.0K |
| Payments For Share Issue Costs | DKK 4.0K | DKK 23.0K | DKK 100.0K |
| Proceeds From Exercise of Warrants | DKK 600.0K | DKK 45.0K | DKK 201.0K |
| Proceeds From Issue of Bonds Notes and Debentures | DKK 28.5M | DKK 0 | DKK 0 |
| Proceeds From Issuing Shares | DKK 0 | DKK 102.6M | DKK 62.0M |
| Research and Development Expense | DKK 60.8M | DKK 140.3M | DKK 186.4M |
| Share Issue Related Cost | DKK 4.0K | DKK 23.0K | DKK 100.0K |
| Trade and Other Current Payables To Trade Suppliers | DKK 5.0M | DKK 8.8M | DKK 17.7M |
Every line item above is a fact tagged in UNION therapeutics A/S's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (DKK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.